Eli Lilly (LLY) Eli Lilly is preparing regulatory application materials for its next-generation weight-loss drug, retatrutide, after positive data from two Phase 3 clinical trials. Sector: Pharmaceuticals / Obesity Treatment Key Highlights: • Advancing retatrutide toward regulatory submission • Follows strong results from two Phase 3 trials • Retatrutide is a triple agonist (GLP-1, GIP, and glucagon) • Positions Lilly to strengthen its leadership in the obesity and cardiometabolic market Why It Matters: Retatrutide has shown impressive efficacy in clinical studies. A successful approval would further expand Lilly’s portfolio in the fast-growing weight-loss drug category, where it already competes strongly with Mounjaro and Zepbound. Ticker: #LLY Focus: Obesity Drugs, Pipeline Advancement https://www.thinksabio.com/reports/isr/LLY